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Introduction: Tasisulam sodium (hereafter referred to as tasisulam) 
is a novel anticancer compound that induces apoptosis and exhibits 
antiangiogenesis activity in a broad range of cancer models, includ-
ing non–small-cell lung cancer (NSCLC).
Methods: Tasisulam was administered as a 2-hour infusion every 
21 days as third-line treatment in patients with advanced (stage 
IIIB/IV) NSCLC.
Results: Thirty-two patients received a C
max
 target dose of 420 g/ml. 
Median time to progression was 3.12 months, median progression-
free survival was 2.69 months, and median overall survival was 
8.48 months. There were no objective responses; 43.8% of patients 
achieved stable disease. A high rate of grade-4 hematologic toxicity 
in the first 30 patients led to exploration of a lower C
max
 target dose 
of 380 g/ml. The rate of grade-4 hematologic toxicity (thrombocy-
topenia and/or neutropenia) at the 380-g/ml dose (n  20) was 20% 
versus 34% at the 420-g/ml dose.
Conclusions: Tasisulam has only modest activity as a third-line treat-
ment of patients with unresectable/metastatic NSCLC. The high rate 
of grade-4 hematologic toxicity observed with this  highly albumin– 
bound compound in this patient population provided challenges for 
fixed C
max
-based dosing. Alternative dosing methods, including 
varying the C
max
 target dose by predose albumin, are under investiga-
tion in other studies.
Key Words: Chemotherapy, Non–small-cell lung cancer, Phase II, 
Tasisulam.
(J Thorac Oncol. 2012;7: 1053–1057)
Tasisulam sodium (hereafter referred to as tasisulam), a novel antineoplastic agent,1 has shown broad activity 
in cancer cell lines, including non–small-cell lung cancer 
(NSCLC), and has a unique activity profile.2 Preclinical in 
vitro data indicate that tasisulam induces apoptosis of tumor 
cells by the intrinsic cell-death pathway,3 and causes an accu-
mulation of cells in the gap 2/mitosis phase of the cell cycle. 
The precise cellular target of tasisulam is under investigation.
In an initial phase-I study, extensive pharmacokinetic 
analysis of tasisulam revealed significant interpatient variabil-
ity in peak plasma concentration (C
max
) and patient tolerability 
with repeated flat dosing, and an unexpectedly high degree of 
high-affinity albumin binding (99.7%–99.9%).4 This led to the 
implementation of a lean body-weight–based5 dosing paradigm 
that reduced pharmacokinetic variability and led to the deter-
mination of the maximum tolerated dose of tasisulam, with a 
C
max
 target of 420 g/ml, which was brought forward into the 
phase-II program. Among the heavily pretreated patients in 
the phase-I study, two patients with NSCLC received at least 
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10 cycles of tasisulam (minimum of 7 months) before disease 
progression, suggesting a possible clinical benefit.
These findings prompted the current phase-II study in 
patients undergoing third-line treatment for metastatic or unre-
sectable NSCLC. The primary objective of this nonrandom-
ized, open-label, multicenter phase-II study was to estimate 
time to progression (TTP). Secondary objectives included 
evaluations of progression-free survival (PFS), duration of 
stable disease, objective response rate, overall survival (oS), 
pharmacokinetics, and safety.
PATIENTS AND METHODS
Patient Eligibility
Key eligibility criteria were male or female sex; age 18 
years or more; histological or cytological diagnosis of unre-
sectable stage IIIB or metastatic NSCLC; two previous sys-
temic treatments, including one prior platinum-based regimen; 
measurable disease, as defined by the Response Evaluation 
Criteria in Solid Tumors6; and Eastern Cooperative oncology 
Group performance status  zero or one. Because tasisulam 
sodium is highly albumin bound, a serum albumin level of 
30 g/l (3.0 g/dl) or more was also required. This study was 
approved by the local Institutional Review Board of each 
participating center. Written informed consent was obtained 
from all patients before they underwent any study procedure 
or received study treatment.
Treatment and Assessments
Tasisulam sodium (Eli Lilly and Company, Indianapolis, 
IN) was administered as a 2-hour (10 minutes) intravenous 
infusion at a target C
max
 of 420 g/ml on day 1 of 21-day 
cycles. A loading dose was administered in cycle 1, followed 
by a chronic dose in subsequent cycles, which was 65% of 
the loading dose. A lower target C
max
 dose of 380 g/ml, with 
a 75% chronic dose, was also investigated. The investigators 
used a validated, Compact Disc—read-only-memory-based 
dosing calculator, and entered the height and weight of the 
patient and the cycle number of treatment (loading or chronic 
dose).4 The dosing calculator provided the dose (in mg) 
required to reach the specific C
max
 target.
The first postbaseline radiographic assessment by com-
puted tomography was performed at the end of cycle 2, with 
subsequent scans performed at the end of every other cycle. 
Radiologic confirmation of response was performed at least 
28 days from response detection, using the same method as 
at baseline. Tumors were evaluated according to Response 
Evaluation Criteria in Solid Tumors Version 1.0.6 Adverse 
events (AEs) were rated using the Common Terminology 
Criteria for Adverse Events, version 3.0. Treatment-related 
AEs were considered  by the investigator to be possibly related 
to the study drug.
Blood samples for cycle 1 were collected at the follow-
ing time points: predose; 2 hours (end of infusion), at one 
time point from 12 to 36 hours, and at one time point from 
72 to 168 hours. The population pharmacokinetic dataset was 
analyzed using the nonlinear mixed-effects modeling program 
NoNMEM (Version 6) with PREDPP (Version V) (ICoN 
plc; Dublin, Ireland).7 The final two-compartment total drug 
model that was developed from the previous phase-I trial4 was 
applied to the current pharmacokinetic analysis.
Statistical Considerations
A sample size sufficient to exclude 2.2 months from 
a 90% confidence interval (CI) would be desired if the true 
median TTP for tasisulam was 4 months. on the basis of 
results from 500 simulated trials under these assumptions, a 
recruitment rate of five patients per month, and a 12-month 
follow-up period for each patient, a sample size of 50 patients 
would provide an 80% probability that the lower limit of the 
90% CI of the median would exclude 2.2 months.8,9
The objective response rate, the clinical benefit rate, 
and the 90% CIs were estimated using unadjusted normal 
approximation for binomial proportions (z approximation). 
Kaplan-Meier analyses, including estimations of 90% CIs, 
were performed on the observed survival distributions of TTP 
and oS.
RESULTS
Between September 2006 and February 2008, 52 patients 
were enrolled in the study at seven study sites in Germany and 
Italy. Thirty-two patients received the original planned target 
C
max
 dose of 420 g/ml (with a chronic dose that was 65% 
of the cycle-1 loading dose). Preliminary review of the ongo-
ing safety data showed that 10 of the first 30 treated patients 
experienced grade-3/4 hematologic toxicity (mainly grade 4) 
during cycle 1, which prompted exploration of a lower target 
C
max
 dose of 380 g/ml, with a chronic dose of 75% (n  20). 
In addition, the cycle-1 loading dose was capped at an abso-
lute maximum dose of 2500 mg at the 380-g/ml dose level. 
Patient characteristics are summarized in Table 1.
Efficacy
Efficacy parameters are summarized in Table 2 and 
Figures 1 and 2. Median TTP was 3.12 months at the origi-
nal target C
max
 dose of 420 g/ml (censoring rate of 12.5%) 
and 1.64 months (censoring rate 25.0%) at C
max
 380 g/ml. 
Median PFS and oS at C
max
 420 g/ml were 2.69 and 8.48 
months, respectively. There were no objective responses; 14 
patients  (43.8%) achieved stable disease (SD) at C
max
 420 g/
ml as did 7 patients (35.0%) at C
max
 380 g/ml; median SD 
durations were 4.21 and 4.93 months, respectively. In the post 
hoc analysis of TTP by histology, median TTP (for both dose 
groups combined) was longer for patients with squamous-cell 
carcinoma (n  12, 4.21 months, 90% CI: 2.69, 5.72) ver-
sus patients with nonsquamous-cell histology (n  31, 2.04 
months, 90% CI: 1.38, 3.52; defined as large-cell carcinoma, 
adenocarcinoma, poorly differentiated carcinoma, and bron-
choalveolar carcinoma; however, this difference was not sig-
nificant (p  0.3297).
Safety
The most common grade-3/4 AEs considered possibly 
related to the study drug (both dose groups) were thrombo-
cytopenia (37%) and neutropenia (29%) (Table 3). Grade-4 
hematologic toxicity (thrombocytopenia and/or neutropenia) 
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occurred in 11 patients (34%) at the target C
max
 dose of 420 
g/ml, most often during cycle 1 (seven patients). At the 380-
g/ml dose level, grade-4 hematologic toxicity occurred in 
4 patients (20%).
Seven deaths were attributed to AEs, of which two 
occurred in the setting of AEs considered possibly related to 
the study drug; these AEs were hypovolemic shock (C
max
 420 
g/ml) with unknown etiology, and respiratory failure (C
max
 
380 g/ml) in the course of radiation pneumonitis, radiation 
pneumonitis/pleuritis, and bronchopneumonia.
Pharmacokinetics
For the target C
max
 doses of 420 and 380 g/ml, cycle-1 
geometric means were 380 g/ml (range, 250–496) and 338 
g/ml (range, 260–440), respectively. observed C
max
 values 
were within 20% of the target dose for 92% (C
max
 420 g/ml) 
and 75% (C
max
 380 g/ml) of the patients. Given the sparse 
sampling in this phase-II study, estimation of pharmacokinetic 
parameters required incorporating the pharmacokinetic data 
from the first human phase-1 study.4 Consistent with previous 
observations,4 tasisulam demonstrated a bi-exponential dispo-
sition pattern with a predicted distribution half-life ranging 
from 0.2 hour to 1.2 hours, and a median terminal elimination 
half-life of 12 days, likely reflecting the high-affinity binding 
of tasisulam to albumin.
DISCUSSION
Second-line therapy with pemetrexed or docetaxel,10 
or second-/third-line therapy with the epidermal growth fac-
tor receptor-tyrosine kinase inhibitor erlotinib8 demonstrated 
response rates of approximately 9%, median TTP of approxi-
mately 3.5 months, and PFS of 2 to 3 months. our study of 
third-line tasisulam administration in NSCLC suggests mod-
est activity, with a median TTP of 3.12 months, no complete 
or partial responses, and a PFS of 2.69 months at C
max
 420 g/
ml. Although there were no responses in the current study, the 
SD rate of 43.8% is comparable with such rates in second- 
to fourth-line treatments for NSCLC (37%–43%).8,10,11 The 
observed PFS (2.69 months at C
max 
420 g/ml) is consistent 
with that in other studies of heavily pretreated patients with 
NSCLC. 8,10,11
The predominant toxicity of tasisulam was bone-marrow 
suppression, particularly grade-4 thrombocytopenia and/or neu-
tropenia. This toxicity proved particularly challenging in this 
heavily pretreated patient population, as these events occurred 
in 11 of 32 patients (34%) at the target C
max
 420-g/ml dose 
level, and were associated with four of the six discontinuations. 
of note, four of the seven patients with grade-4 thrombocytope-
nia and/or neutropenia in cycle 1 had clinical signs of disease 
TABLE 1. Baseline Demographics and Disease 
Characteristics
Characteristic
Target C
max
  
420 mg/ml  
(N  32)
Target C
max
  
380 m/ml  
(N = 20) Total (N  52)
Age, median 
(range), yrs
61.5 (38.0–73.0) 61.0 (45.0–73.0) 61.0 (38.0–73.0)
Sex, n (%)
 Female 7 (21.9) 6 (30.0) 13 (25.0)
 Male 25 (78.1) 14 (70.0) 39 (75.0)
Race, n (%)
 Caucasian 32 (100.0) 20 (100.0) 52 (100.0)
Pathological diagnosis, n (%)
 Sq uamous-cell 
carcinoma
11 (34.4) 7 (35.0) 18 (34.6)
 No nsquamous-
cell carcinoma
21 (65.6) 13 (65.0) 34 (65.4)
 Adenocarcinoma 12 (37.5) 12 (60.0) 24 (46.2)
 Po orly 
differentiated 
NSCLC
6 (18.8) 1 (5.0) 7 (13.5)
 La rge-cell 
carcinoma
2 (6.3) 0 (0.0) 2 (3.8)
 Br onchoalveolar 
carcinoma
1 (3.1) 0 (0.0) 1 (1.9)
Disease stage, n (%)
 Stage IIIB 5 (15.6) 4 (20.0) 9 (17.3)
 Stage IV 27 (84.4) 16 (80.0) 43 (82.7)
ECoG performance status, n (%)
 0 19 (59.4) 10 (50.0) 29 (55.8)
 1 13 (40.6) 10 (50.0) 23 (44.2)
Smoking status, n (%)
 yes 6 (18.8) 5 (25.0) 11 (21.2)
 No 18 (56.3) 12 (60.0) 30 (57.7)
 Mi ssing/not 
assessed
8 (25.0) 3 (15.0) 11 (21.2)
Some percentages do not add up to 100 because of rounding.
ECoG, Eastern Cooperative oncology Group; N, number of patients; NSCLC, 
non–small-cell lung cancer.
TABLE 2. Efficacy Parameters
Parameters
Target C
max
  
420 mg/ml  
(N  32)
Target C
max  
380 mg/ml  
(N  20)
Time-to-Event Parameters, 90% CI, months
 Median time to progressiona 3.12 (2.04–4.21) 1.64 (1.35–5.19)
 M edian progression-free 
survivalb
2.69 (1.38–4.17) 1.43 (1.31–3.22)
 Median overall survivalc 8.48 (5.06–10.15) 7.97 (4.07–12.06)
Response
 ob jective response (CR or 
PR), n (%)
0 (0.0) 0 (0.0)
 Stable disease, n (%) 14 (43.8) 7 (35.0)
 Progressive disease, n (%) 7 (21.9) 7 (35.0)
 Unknown, n (%) 11 (34.4) 6 (30.0)
 Me dian duration of stable 
diseased (90% CI), months
4.21 (3.58–5.72) 4.93 (3.22–10.35)
aTime from the date of the first dose to the first date of progressive disease or death 
from study disease.
bTime from the date of the first dose to the first date of progressive disease or death 
from any cause.
cTime from the date of the first dose to the date of death from any cause.
dTime from the date of the first dose until documented progressive disease. The 
minimal time interval required between two measurements for determination of stable 
disease was 6 weeks (72 hours). 
CI, confidence interval; CR, complete response, PR, partial response.
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FIGURE 1. Kaplan-Meier curve for time to progression (TTP). Circles represent censored observations. The probabilities 
of not progressing at 3, 6, 9, and 12 months are shown below the graph. CI, confidence interval; 380 g/ml, target Cmax of 
380 g/ml (n  20; censoring rate  25.0%); 420 g/ml, target Cmax of 420 g/ml (n  32; censoring rate  12.5%).
FIGURE 2. Kaplan-Meier curve for overall survival (OS). Circles represent censored observations. The probabilities being 
alive at 3, 6, 9, 12, and 15 months are shown below the graph. CI, confidence interval; 380 g/ml, target Cmax of 380 g/
ml (n  20; censoring rate  40.0%); 420 g/ml, target Cmax of 420 g/ml (n  32; censoring rate  21.9%).
progression, suggesting that tumor-related cachexia and declin-
ing albumin (to which tasisulam is highly bound) may also have 
contributed to the development of this toxicity.
The exploratory, lower dose of tasisulam (target C
max
 of 
380 g/ml) was associated with a lower rate of grade-4 throm-
bocytopenia and/or neutropenia (four of 20 patients; 20%); 
median TTP and PFS were 1.64 months and 1.43 months, 
respectively. Although the small sample sizes precluded for-
mal statistical efficacy/safety comparison of the C
max
 dosing 
groups, these results suggest that a fixed reduction in target 
C
max
 dose for all patients may not have provided the optimal 
balance of efficacy and safety.
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In summary, tasisulam administered as a 2-hour infu-
sion in 21-day cycles only had modest activity as a third-line 
treatment of patients with metastatic or unresectable NSCLC. 
Although the nonhematologic toxicity profile of tasisulam 
was relatively favorable relative to standard chemotherapeutic 
agents like taxanes and cisplatin, bone-marrow suppression 
proved dose limiting in this heavily pretreated patient popula-
tion. Lowering the target C
max
 dose of tasisulam was associated 
with a lower risk of grade-4 hematologic toxicity, but further 
studies will be required to identify pharmacokinetic and 
patient factors that might further optimize dosing. Alternative 
dosing methods, including varying the target C
max
 dose by pre-
dose albumin, are under investigation in other studies.
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TABLE 3. Incidence of Drug-Related Treatment-Emergent 
Adverse Events,a n (%)
Adverse Events
Target C
max
 420 g/
ml (N32)
Target C
max
 380  
/ml (N20)
Grade 3 Grade 4 Grade 3 Grade 4
Hematologic
 Thrombocytopenia 3 (9.4) 11 (34.4) 2 (10.0) 3 (15.0)
 Neutropenia 4 (12.5) 5 (15.6) 4 (20.0) 2 (10.0)
 Anemia 4 (12.5) 1 (3.1) 1 (5.0) 0 (0.0)
 Leukopenia 2 (6.3) 1 (3.1) 0 (0.0) 1 (5.0)
 Blood/bone-marrow/other 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0)
Nonhematologic
 Febrile neutropenia 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0)
 Diarrhea 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0)
 Dyspnea 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0)
 Fatigue 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0)
 Fever 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0)
 Hyperglycemia 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0)
 Nausea 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0)
 Pneumonia 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0)
 Pn eumonitis/pulmonary 
infiltrates
0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0)
 Rash: acne/acneform 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0)
 Sinus tachycardia 0 (0.0) 1 (3.1) 0 (0.0) 0 (0.0)
CTCAE, Common Terminology Criteria for Adverse Events, version 3; MedDRA, 
Medical Dictionary for Regulatory Activities.
aMedDRA terms with CTCAE, version 3.0, grading.
